# Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

> **NCT01394952** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 9901 (actual)

## Conditions studied

- Cardiovascular Disease
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01394952
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-22
- **Primary completion:** 2018-08-21
- **Final completion:** 2018-08-21
- **Target enrollment:** 9901 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394952, "Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01394952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*